For many biopharmas, it takes years of hard work to transition from being a clinical-stage drugmaker to a commercial one. Companies rarely want to make the shift back. But after a years-long uphill ...
Lexicon Pharmaceuticals announced that it received a complete response letter (CRL) from the FDA regarding its New Drug Application for Zynquista™ (sotagliflozin), which was proposed as an adjunct to ...
Lexicon has pivoted back to a research-driven biotech model, abandoning internal drug marketing to focus on clinical development and out-licensing. Pilavapadin's upcoming Phase II readout is critical, ...
The last time I spoke about Lexicon Pharmaceuticals, Inc. (LXRX) it was with respect to a Seeking Alpha article entitled "Advisory Panel Votes In Split Fashion For Lexicon's Drug: What does That Mean ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results